logo
logo

Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics

Sep 10, 2020•almost 5 years ago

Amount Raised

$91 Million

Round Type

series a

Cambridge

Description

Korro Bio, Inc. today announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies.

Company Information

Company

Korro Bio

Location

Cambridge, Maryland, United States

About

Korro Bio is creating transformative therapeutics for patients by selectively editing messenger RNA to recode specific codons to deliver a beneficial change in protein sequence, structure, and function.

FundzWatch™ Score

63
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech